nach oben

Current Hematologic Malignancy Reports

Erschienen in:

14.02.2018 | T-Cell and Other Lymphoproliferative Malignancies (J Zain, Section Editor)

Updates of Peripheral T Cell Lymphomas Based on the 2017 WHO Classification

verfasst von: Parwiz J. Siaghani, Joo Y. Song

Erschienen in: Current Hematologic Malignancy Reports | Ausgabe 1/2018

Einloggen, um Zugang zu erhalten

Abstract

Purpose of Review

This review will describe and update the readers on the recent changes of the 2017 WHO classification in regard to peripheral T cell lymphomas.

Recent Findings

Significant advances in molecular studies have resulted in revisions of the classification as well as introduction of provisional entities (such as breast implant-associated ALCL, nodal PTCL with TFH phenotype).

Summary

Major advances in molecular and gene expression profiling have expanded our knowledge of T cell lymphomas, including updates in the diagnostic criteria and sub-classification which will facilitate in improving patient care and research.

• Swerdlow SH, Campo E, Harris NL, et al. WHO classification of Tumours of Haematopoietic and Lymphoid Tissues (ed revised 4th): International Agency for Research on Cancer Lyon; 2017. This reference was particularly of interest because it highlights updates as well as the theory behind the changes in the classification for 2017 described by the Editors of the WHO.

Vose J, Armitage J, Weisenburger D. International peripheral T-cell and natural killer/T-cell lymphoma study: pathology findings and clinical outcomes. J Clin Oncol. 2008;26(25):4124–30. https://doi.org/10.1200/JCO.2008.16.4558.CrossRefPubMed

Hsi ED, Said J, Macon WR, et al. Diagnostic accuracy of a defined immunophenotypic and molecular genetic approach for peripheral T/NK-cell lymphomas. A North American PTCL study group project. Am J Surg Pathol. 2014;38(6):768–75.CrossRefPubMedPubMedCentral

•• Iqbal J, Wright G, Wang C, et al. Gene expression signatures delineate biological and prognostic subgroups in peripheral T-cell lymphoma. Blood. 2014;123(19):2915–23. This article is also of higher interest because it studied gene expression profiles of over 350 PTCLs and identified to major molecular subgroups that are important for prognosis (GATA3 and TBX21). CrossRefPubMedPubMedCentral

Swerdlow SH, Campo E, Pileri SA, et al. The 2016 revision of the World Health Organization classification of lymphoid neoplasms. Blood. 2016;127(20):2375–90.CrossRefPubMedPubMedCentral

Attygalle AD, Cabecadas J, Gaulard P, et al. Peripheral T-cell and NK-cell lymphomas and their mimics; taking a step forward - report on the lymphoma workshop of the XVIth meeting of the European Association for Haematopathology and the Society for Hematopathology. Histopathology. 2014;64(2):171–99.CrossRefPubMed

Huang Y, Moreau A, Dupuis J, et al. Peripheral T-cell lymphomas with a follicular growth pattern are derived from follicular helper T cells (TFH) and may show overlapping features with angioimmunoblastic T-cell lymphomas. Am J Surg Pathol. 2009;33(5):682–90.CrossRefPubMedPubMedCentral

Rodriguez-Pinilla SM, Atienza L, Murillo C, et al. Peripheral T-cell lymphoma with follicular T-cell markers. Am J Surg Pathol. 2008;32(12):1787–99.CrossRefPubMed

Hu S, Young KH, Konoplev SN, Medeiros LJ. Follicular T-cell lymphoma: a member of an emerging family of follicular helper T-cell derived T-cell lymphomas. Hum Pathol. 2012;43(11):1789–98. https://doi.org/10.1016/j.humpath.2012.05.002.CrossRefPubMed

10.

Odejide O, Weigert O, Lane AA, et al. A targeted mutational landscape of angioimmunoblastic T-cell lymphoma. Blood. 2014;123(9):1293–6.CrossRefPubMedPubMedCentral

11.

Lemonnier F, Couronne L, Parrens M, et al. Recurrent TET2 mutations in peripheral T-cell lymphomas correlate with TFH-like features and adverse clinical parameters. Blood. 2012;120(7):1466–9.CrossRefPubMed

12.

Ondrejka SL, Grzywacz B, Bodo J, et al. Angioimmunoblastic T-cell lymphomas with the RHOA p.Gly17Val mutation have classic clinical and pathologic features. Am J Surg Pathol. 2016;40(3):335–41.CrossRefPubMed

13.

Jaffe ES, Nicolae A, Pittaluga S. Peripheral T-cell and NK-cell lymphomas in the WHO classification: pearls and pitfalls. Mod Pathol. 2013;26(Suppl 1):S71–87. https://doi.org/10.1038/modpathol.2012.181.CrossRefPubMed

14.

Attygalle AD, Kyriakou C, Dupuis J, et al. Histologic evolution of angioimmunoblastic T-cell lymphoma in consecutive biopsies: clinical correlation and insights into natural history and disease progression. Am J Surg Pathol. 2007;31(7):1077–88.CrossRefPubMed

15.

Rodriguez-Justo M, Attygalle AD, Munson P, Roncador G, Marafioti T, Piris MA. Angioimmunoblastic T-cell lymphoma with hyperplastic germinal centres: a neoplasia with origin in the outer zone of the germinal centre? Clinicopathological and immunohistochemical study of 10 cases with follicular T-cell markers. Mod Pathol. 2009;22(6):753–61. https://doi.org/10.1038/modpathol.2009.12.CrossRefPubMed

16.

Nicolae A, Pittaluga S, Venkataraman G, et al. Peripheral T-cell lymphomas of follicular T-helper cell derivation with Hodgkin/Reed-Sternberg cells of B-cell lineage: both EBV-positive and EBV-negative variants exist. Am J Surg Pathol. 2013;37(6):816–26.CrossRefPubMedPubMedCentral

17.

Zettl A, Lee S, Rudiger T, et al. Epstein-Barr virus-associated B-cell lymphoproliferative disorders in angioimmunoblastic T-cell lymphoma and peripheral T-cell lymphoma, unspecified. Am J Clin Pathol. 2002;117(3):368–79.CrossRefPubMed

18.

Federico M, Rudiger T, Bellei M, et al. Clinicopathologic characteristics of angioimmunoblastic T-cell lymphoma: analysis of the international peripheral T-cell lymphoma project. J Clin Oncol. 2013;31(2):240–6.CrossRefPubMed

19.

Agostinelli C, Hartmann S, Klapper W, et al. Peripheral T cell lymphomas with follicular T helper phenotype: a new basket or a distinct entity? Revising Karl Lennert’s personal archive. Histopathology. 2011;59(4):679–91.CrossRefPubMed

20.

Moroch J, Copie-Bergman C, de Leval L, et al. Follicular peripheral T-cell lymphoma expands the spectrum of classical Hodgkin lymphoma mimics. Am J Surg Pathol. 2012;36(11):1636–46.CrossRefPubMed

21.

de Leval L, Rickman DS, Thielen C, Reynies A, Huang YL, Delsol G, et al. The gene expression profile of nodal peripheral T-cell lymphoma demonstrates a molecular link between angioimmunoblastic T-cell lymphoma (AITL) and follicular helper T (TFH) cells. Blood. 2007;109(11):4952–63. https://doi.org/10.1182/blood-2006-10-055145.CrossRefPubMed

22.

Dobay MP, Lemonnier F, Missiaglia E, et al. Integrative clinicopathological and molecular analyses of angioimmunoblastic T-cell lymphoma and other nodal lymphomas of follicular helper T-cell origin. Haematologica. 2017;102(4):e148–51.CrossRefPubMedPubMedCentral

23.

Palomero T, Couronne L, Khiabanian H, et al. Recurrent mutations in epigenetic regulators, RHOA and FYN kinase in peripheral T cell lymphomas. Nat Genet. 2014;46(2):166–70.CrossRefPubMedPubMedCentral

24.

Sakata-Yanagimoto M, Enami T, Yoshida K, et al. Somatic RHOA mutation in angioimmunoblastic T cell lymphoma. Nat Genet. 2014;46(2):171–5.CrossRefPubMed

25.

Wang C, McKeithan TW, Gong Q, Zhang W, Bouska A, Rosenwald A, et al. IDH2R172 mutations define a unique subgroup of patients with angioimmunoblastic T-cell lymphoma. Blood. 2015;126(15):1741–52. https://doi.org/10.1182/blood-2015-05-644591.CrossRefPubMedPubMedCentral

26.

Yoo HY, Sung MK, Lee SH, Kim S, Lee H, Park S, et al. A recurrent inactivating mutation in RHOA GTPase in angioimmunoblastic T cell lymphoma. Nat Genet. 2014;46(4):371–5. https://doi.org/10.1038/ng.2916.CrossRefPubMed

27.

Quivoron C, Couronne L, Della Valle V, et al. TET2 inactivation results in pleiotropic hematopoietic abnormalities in mouse and is a recurrent event during human lymphomagenesis. Cancer Cell. 2011;20(1):25–38. https://doi.org/10.1016/j.ccr.2011.06.003.CrossRefPubMed

28.

Cairns RA, Iqbal J, Lemonnier F, Kucuk C, de Leval L, Jais JP, et al. IDH2 mutations are frequent in angioimmunoblastic T-cell lymphoma. Blood. 2012;119(8):1901–3. https://doi.org/10.1182/blood-2011-11-391748.CrossRefPubMedPubMedCentral

29.

Streubel B, Vinatzer U, Willheim M, Raderer M, Chott A. Novel t(5;9)(q33;q22) fuses ITK to SYK in unspecified peripheral T-cell lymphoma. Leukemia. 2006;20(2):313–8. https://doi.org/10.1038/sj.leu.2404045.CrossRefPubMed

30.

Dierks C, Adrian F, Fisch P, et al. The ITK-SYK fusion oncogene induces a T-cell lymphoproliferative disease in mice mimicking human disease. Cancer Res. 2010;70(15):6193–204.CrossRefPubMed

31.

Attygalle AD, Feldman AL, Dogan A. ITK/SYK translocation in angioimmunoblastic T-cell lymphoma. Am J Surg Pathol. 2013;37(9):1456–7. https://doi.org/10.1097/PAS.0b013e3182991415.CrossRefPubMed

32.

Rizvi MA, Evens AM, Tallman MS, Nelson BP, Rosen ST. T-cell non-Hodgkin lymphoma. Blood. 2006;107(4):1255–64. https://doi.org/10.1182/blood-2005-03-1306.CrossRefPubMed

33.

Menon MP, Nicolae A, Meeker H, et al. Primary CNS T-cell lymphomas: a clinical, morphologic, Immunophenotypic, and molecular analysis. Am J Surg Pathol. 2015;39(12):1719–29.CrossRefPubMedPubMedCentral

34.

Hayashi E, Takata K, Sato Y, Tashiro Y, Tachiyama Y, Sawada-Kitamura S, et al. Distinct morphologic, phenotypic, and clinical-course characteristics of indolent peripheral T-cell lymphoma. Hum Pathol. 2013;44(9):1927–36. https://doi.org/10.1016/j.humpath.2013.03.002.CrossRefPubMed

35.

Bellei M, Sabattini E, Pesce EA, et al. Pitfalls and major issues in the histologic diagnosis of peripheral T-cell lymphomas: results of the central review of 573 cases from the T-Cell Project, an international, cooperative study. Hematol Oncol. 2016.

36.

Swerdlow SH, Jaffe ES, Brousset P, Chan JK, de Leval L, Gaulard P, et al. Cytotoxic T-cell and NK-cell lymphomas: current questions and controversies. Am J Surg Pathol. 2014;38(10):e60–71. https://doi.org/10.1097/PAS.0000000000000295.CrossRefPubMed

37.

Went P, Agostinelli C, Gallamini A, Piccaluga PP, Ascani S, Sabattini E, et al. Marker expression in peripheral T-cell lymphoma: a proposed clinical-pathologic prognostic score. J Clin Oncol. 2006;24(16):2472–9. https://doi.org/10.1200/JCO.2005.03.6327.CrossRefPubMed

38.

Sabattini E, Pizzi M, Tabanelli V, et al. CD30 expression in peripheral T-cell lymphomas. Haematologica. 2013;98(8):e81–2.CrossRefPubMedPubMedCentral

39.

Barry TS, Jaffe ES, Sorbara L, Raffeld M, Pittaluga S. Peripheral T-cell lymphomas expressing CD30 and CD15. Am J Surg Pathol. 2003;27(12):1513–22. https://doi.org/10.1097/00000478-200312000-00003.CrossRefPubMed

40.

Geissinger E, Odenwald T, Lee SS, et al. Nodal peripheral T-cell lymphomas and, in particular, their lymphoepithelioid (Lennert’s) variant are often derived from CD8(+) cytotoxic T-cells. Virchows Arch. 2004;445(4):334–43.CrossRefPubMed

41.

Hartmann S, Agostinelli C, Klapper W, et al. Revising the historical collection of epithelioid cell-rich lymphomas of the Kiel lymph node registry: what is Lennert's lymphoma nowadays? Histopathology. 2011;59(6):1173–82.CrossRefPubMed

42.

Ha SY, Sung J, Ju H, Karube K, Kim SJ, Kim WS, et al. Epstein-Barr virus-positive nodal peripheral T cell lymphomas: clinicopathologic and gene expression profiling study. Pathol Res Pract. 2013;209(7):448–54. https://doi.org/10.1016/j.prp.2013.04.013.CrossRefPubMed

43.

Swerdlow SH. T-cell and NK-cell posttransplantation lymphoproliferative disorders. Am J Clin Pathol. 2007;127(6):887–95. https://doi.org/10.1309/LYXN3RGF7D7KPYG0.CrossRefPubMed

44.

Piccaluga PP, Fuligni F, De Leo A, et al. Molecular profiling improves classification and prognostication of nodal peripheral T-cell lymphomas: results of a phase III diagnostic accuracy study. J Clin Oncol. 2013;31(24):3019–25.CrossRefPubMed

45.

Laginestra MA, Piccaluga PP, Fuligni F, Rossi M, Agostinelli C, Righi S, et al. Pathogenetic and diagnostic significance of microRNA deregulation in peripheral T-cell lymphoma not otherwise specified. Blood Cancer J. 2014;4(11):259. https://doi.org/10.1038/bcj.2014.78.CrossRefPubMedPubMedCentral

46.

Liu C, Iqbal J, Teruya-Feldstein J, et al. MicroRNA expression profiling identifies molecular signatures associated with anaplastic large cell lymphoma. Blood. 2013;122(12):2083–92.CrossRefPubMedPubMedCentral

47.

Piva R, Agnelli L, Pellegrino E, et al. Gene expression profiling uncovers molecular classifiers for the recognition of anaplastic large-cell lymphoma within peripheral T-cell neoplasms. J Clin Oncol. 2010;28(9):1583–90.CrossRefPubMed

48.

Wang T, Feldman AL, Wada DA, Lu Y, Polk A, Briski R, et al. GATA-3 expression identifies a high-risk subset of PTCL, NOS with distinct molecular and clinical features. Blood. 2014;123(19):3007–15. https://doi.org/10.1182/blood-2013-12-544809.CrossRefPubMedPubMedCentral

49.

•• Parrilla Castellar ER, Jaffe ES, Said JW, et al. ALK-negative anaplastic large cell lymphoma is a genetically heterogeneous disease with widely disparate clinical outcomes. Blood. 2014;124(9):1473–80. This article is of high interest because it describes translocations in ALCL, ALK-negative that were not previously described ( DUSP22 and TP63 ). CrossRefPubMedPubMedCentral

50.

Hapgood G, Savage KJ. The biology and management of systemic anaplastic large cell lymphoma. Blood. 2015;126(1):17–25. https://doi.org/10.1182/blood-2014-10-567461.CrossRefPubMed

51.

Stein H, Foss HD, Durkop H, et al. CD30(+) anaplastic large cell lymphoma: a review of its histopathologic, genetic, and clinical features. Blood. 2000;96(12):3681–95.PubMed

52.

Xing X, Feldman AL. Anaplastic large cell lymphomas: ALK positive, ALK negative, and primary cutaneous. Adv Anat Pathol. 2015;22(1):29–49. https://doi.org/10.1097/PAP.0000000000000047.CrossRefPubMed

53.

King RL, Dao LN, ED MP, et al. Morphologic features of ALK-negative anaplastic large cell lymphomas with DUSP22 rearrangements. Am J Surg Pathol. 2016;40(1):36–43. https://doi.org/10.1097/PAS.0000000000000500.CrossRefPubMedPubMedCentral

54.

Eberle FC, Song JY, Xi L, Raffeld M, Harris NL, Wilson WH, et al. Nodal involvement by cutaneous CD30-positive T-cell lymphoma mimicking classical Hodgkin lymphoma. Am J Surg Pathol. 2012;36(5):716–25. https://doi.org/10.1097/PAS.0b013e3182487158.CrossRefPubMedPubMedCentral

55.

Wang X, Boddicker RL, Dasari S, Sidhu JS, Kadin ME, Macon WR, et al. Expression of p63 protein in anaplastic large cell lymphoma: implications for genetic subtyping. Hum Pathol. 2017;64:19–27. https://doi.org/10.1016/j.humpath.2017.01.003.CrossRefPubMed

56.

Miranda RN, Aladily TN, Prince HM, et al. Breast implant-associated anaplastic large-cell lymphoma: long-term follow-up of 60 patients. J Clin Oncol. 2014;32(2):114–20. https://doi.org/10.1200/JCO.2013.52.7911.CrossRefPubMed

57.

Brody GS, Deapen D, Taylor CR, et al. Anaplastic large cell lymphoma occurring in women with breast implants: analysis of 173 cases. Plast Reconstr Surg. 2015;135(3):695–705.CrossRefPubMed

58.

de Jong D, Vasmel WL, de Boer JP, Verhave G, Barbé E, Casparie MK, et al. Anaplastic large-cell lymphoma in women with breast implants. JAMA. 2008;300(17):2030–5. https://doi.org/10.1001/jama.2008.585.CrossRefPubMed

59.

Doren EL, Miranda RN, Selber JC, Garvey PB, Liu J, Medeiros LJ, et al. U.S. epidemiology of breast implant-associated anaplastic large cell lymphoma. Plast Reconstr Surg. 2017;139(5):1042–50. https://doi.org/10.1097/PRS.0000000000003282.CrossRefPubMed

60.

Largent J, Oefelein M, Kaplan HM, Okerson T, Boyle P. Risk of lymphoma in women with breast implants: analysis of clinical studies. Eur J Cancer Prev. 2012;21(3):274–80. https://doi.org/10.1097/CEJ.0b013e328350b0ae.CrossRefPubMed

61.

Roden AC, Macon WR, Keeney GL, Myers JL, Feldman AL, Dogan A. Seroma-associated primary anaplastic large-cell lymphoma adjacent to breast implants: an indolent T-cell lymphoproliferative disorder. Mod Pathol. 2008;21(4):455–63. https://doi.org/10.1038/modpathol.3801024.CrossRefPubMed

62.

Taylor CR, Siddiqi IN, Brody GS. Anaplastic large cell lymphoma occurring in association with breast implants: review of pathologic and immunohistochemical features in 103 cases. Appl Immunohistochem Mol Morphol. 2013;21(1):13–20. https://doi.org/10.1097/PAI.0b013e318266476c.PubMed

63.

van Wijk F, Cheroutre H. Intestinal T cells: facing the mucosal immune dilemma with synergy and diversity. Semin Immunol. 2009;21(3):130–8. https://doi.org/10.1016/j.smim.2009.03.003.CrossRefPubMedPubMedCentral

64.

Delabie J, Holte H, Vose JM, et al. Enteropathy-associated T-cell lymphoma: clinical and histological findings from the international peripheral T-cell lymphoma project. Blood. 2011;118(1):148–55.CrossRefPubMed

65.

Tan SY, Chuang SS, Tang T, Tan L, Ko YH, Chuah KL, et al. Type II EATL (epitheliotropic intestinal T-cell lymphoma): a neoplasm of intra-epithelial T-cells with predominant CD8alphaalpha phenotype. Leukemia. 2013;27(8):1688–96. https://doi.org/10.1038/leu.2013.41.CrossRefPubMed

66.

Wilson AL, Swerdlow SH, Przybylski GK, Surti U, Choi JK, Campo E, et al. Intestinal gammadelta T-cell lymphomas are most frequently of type II enteropathy-associated T-cell type. Hum Pathol. 2013;44(6):1131–45. https://doi.org/10.1016/j.humpath.2012.10.002.CrossRefPubMedPubMedCentral

67.

Chan JK, Chan AC, Cheuk W, Wan SK, Lee WK, Lui YH, et al. Type II enteropathy-associated T-cell lymphoma: a distinct aggressive lymphoma with frequent gammadelta T-cell receptor expression. Am J Surg Pathol. 2011;35(10):1557–69. https://doi.org/10.1097/PAS.0b013e318222dfcd.CrossRefPubMed

68.

Kikuma K, Yamada K, Nakamura S, et al. Detailed clinicopathological characteristics and possible lymphomagenesis of type II intestinal enteropathy-associated T-cell lymphoma in Japan. Hum Pathol. 2014;45(6):1276–84.CrossRefPubMed

69.

Deleeuw RJ, Zettl A, Klinker E, et al. Whole-genome analysis and HLA genotyping of enteropathy-type T-cell lymphoma reveals 2 distinct lymphoma subtypes. Gastroenterology. 2007;132(5):1902–11. https://doi.org/10.1053/j.gastro.2007.03.036.CrossRefPubMed

70.

Perry AM, Warnke RA, Hu Q, Gaulard P, Copie-Bergman C, Alkan S, et al. Indolent T-cell lymphoproliferative disease of the gastrointestinal tract. Blood. 2013;122(22):3599–606. https://doi.org/10.1182/blood-2013-07-512830.CrossRefPubMedPubMedCentral

71.

Matnani R, Ganapathi KA, Lewis SK, Green PH, Alobeid B, Bhagat G. Indolent T- and NK-cell lymphoproliferative disorders of the gastrointestinal tract: a review and update. Hematol Oncol. 2017;35(1):3–16. https://doi.org/10.1002/hon.2317.CrossRefPubMed

72.

Margolskee E, Jobanputra V, Lewis SK, Alobeid B, Green PH, Bhagat G. Indolent small intestinal CD4+ T-cell lymphoma is a distinct entity with unique biologic and clinical features. PLoS One. 2013;8(7):e68343. https://doi.org/10.1371/journal.pone.0068343.CrossRefPubMedPubMedCentral

73.

Catassi C, Bearzi I, Holmes GK. Association of celiac disease and intestinal lymphomas and other cancers. Gastroenterology. 2005;128(4 Suppl 1):S79–86.CrossRefPubMed

74.

Sharaiha RZ, Lebwohl B, Reimers L, Bhagat G, Green PH, Neugut AI. Increasing incidence of enteropathy-associated T-cell lymphoma in the United States, 1973-2008. Cancer. 2012;118(15):3786–92. https://doi.org/10.1002/cncr.26700.CrossRefPubMed

75.

Malamut G, Chandesris O, Verkarre V, et al. Enteropathy associated T cell lymphoma in celiac disease: a large retrospective study. Dig Liver Dis. 2013;45(5):377–84.CrossRefPubMed

76.

van de Water JM, Cillessen SA, Visser OJ, Verbeek WH, Meijer CJ, Mulder CJ. Enteropathy associated T-cell lymphoma and its precursor lesions. Best Pract Res Clin Gastroenterol. 2010;24(1):43–56. https://doi.org/10.1016/j.bpg.2009.11.002.CrossRefPubMed

77.

Silano M, Volta U, Vincenzi AD, Dessi M, Vincenzi MD, Collaborating Centers of the Italian Registry of the Complications of Coeliac D. Effect of a gluten-free diet on the risk of enteropathy-associated T-cell lymphoma in celiac disease. Dig Dis Sci. 2008;53(4):972–6. https://doi.org/10.1007/s10620-007-9952-8.CrossRefPubMed

78.

Green PH, Cellier C. Celiac disease. N Engl J Med. 2007;357(17):1731–43. https://doi.org/10.1056/NEJMra071600.CrossRefPubMed

79.

Megiorni F, Pizzuti A. HLA-DQA1 and HLA-DQB1 in celiac disease predisposition: practical implications of the HLA molecular typing. J Biomed Sci. 2012;19(1):88. https://doi.org/10.1186/1423-0127-19-88.CrossRefPubMedPubMedCentral

80.

Malamut G, Afchain P, Verkarre V, et al. Presentation and long-term follow-up of refractory celiac disease: comparison of type I with type II. Gastroenterology. 2009;136(1):81–90.CrossRefPubMed

81.

Amiot A, Allez M, Treton X, et al. High frequency of fatal haemophagocytic lymphohistiocytosis syndrome in enteropathy-associated T cell lymphoma. Dig Liver Dis. 2012;44(4):343–9.CrossRefPubMed

82.

Berman EL, Zauber NP, Rickert RR, Diss TC, Isaacson PG. Enteropathy-associated T cell lymphoma with brain involvement. J Clin Gastroenterol. 1998;26(4):337–41. https://doi.org/10.1097/00004836-199806000-00026.CrossRefPubMed

83.

Gobbi C, Buess M, Probst A, et al. Enteropathy-associated T-cell lymphoma with initial manifestation in the CNS. Neurology. 2003;60(10):1718–9.CrossRefPubMed

84.

Malamut G, Meresse B, Cellier C, Cerf-Bensussan N. Refractory celiac disease: from bench to bedside. Semin Immunopathol. 2012;34(4):601–13. https://doi.org/10.1007/s00281-012-0322-z.CrossRefPubMed

85.

de Mascarel A, Belleannee G, Stanislas S, et al. Mucosal intraepithelial T-lymphocytes in refractory celiac disease: a neoplastic population with a variable CD8 phenotype. Am J Surg Pathol. 2008;32(5):744–51.CrossRefPubMed

86.

Farstad IN, Johansen FE, Vlatkovic L, Jahnsen J, Scott H, Fausa O, et al. Heterogeneity of intraepithelial lymphocytes in refractory sprue: potential implications of CD30 expression. Gut. 2002;51(3):372–8. https://doi.org/10.1136/gut.51.3.372.CrossRefPubMedPubMedCentral

87.

Tack GJ, van Wanrooij RL, Langerak AW, et al. Origin and immunophenotype of aberrant IEL in RCDII patients. Mol Immunol. 2012;50(4):262–70. https://doi.org/10.1016/j.molimm.2012.01.014.CrossRefPubMed

88.

Schmitz F, Tjon JM, Lai Y, et al. Identification of a potential physiological precursor of aberrant cells in refractory coeliac disease type II. Gut. 2013;62(4):509–19. https://doi.org/10.1136/gutjnl-2012-302265.CrossRefPubMed

89.

Zettl A, Ott G, Makulik A, et al. Chromosomal gains at 9q characterize enteropathy-type T-cell lymphoma. Am J Pathol. 2002;161(5):1635–45.CrossRefPubMedPubMedCentral

90.

Nicolae A, Xi L, Pham TH, et al. Mutations in the JAK/STAT and RAS signaling pathways are common in intestinal T-cell lymphomas. Leukemia. 2016;30(11):2245–7.CrossRefPubMedPubMedCentral

91.

Kucuk C, Jiang B, Hu X, et al. Activating mutations of STAT5B and STAT3 in lymphomas derived from gammadelta-T or NK cells. Nat Commun. 2015;6:6025. https://doi.org/10.1038/ncomms7025.CrossRefPubMed

92.

Garcia-Herrera A, Song JY, Chuang SS, Villamor N, Colomo L, Pittaluga S, et al. Nonhepatosplenic gammadelta T-cell lymphomas represent a spectrum of aggressive cytotoxic T-cell lymphomas with a mainly extranodal presentation. Am J Surg Pathol. 2011;35(8):1214–25. https://doi.org/10.1097/PAS.0b013e31822067d1.CrossRefPubMedPubMedCentral

93.

Tse E, Gill H, Loong F, et al. Type II enteropathy-associated T-cell lymphoma: a multicenter analysis from the Asia Lymphoma Study Group. Am J Hematol. 2012;87(7):663–8.CrossRefPubMed

94.

Tan SY, Ooi AS, Ang MK, Koh M, Wong JC, Dykema K, et al. Nuclear expression of MATK is a novel marker of type II enteropathy-associated T-cell lymphoma. Leukemia. 2011;25(3):555–7. https://doi.org/10.1038/leu.2010.295.CrossRefPubMed

95.

Chott A, Haedicke W, Mosberger I, et al. Most CD56+ intestinal lymphomas are CD8+CD5-T-cell lymphomas of monomorphic small to medium size histology. Am J Pathol. 1998;153(5):1483–90.CrossRefPubMedPubMedCentral

96.

Tomita S, Kikuti YY, Carreras J, Kojima M, Ando K, Takasaki H, et al. Genomic and immunohistochemical profiles of enteropathy-associated T-cell lymphoma in Japan. Mod Pathol. 2015;28(10):1286–96. https://doi.org/10.1038/modpathol.2015.85.CrossRefPubMed

97.

Sun J, Lu Z, Yang D, Chen J. Primary intestinal T-cell and NK-cell lymphomas: a clinicopathological and molecular study from China focused on type II enteropathy-associated T-cell lymphoma and primary intestinal NK-cell lymphoma. Mod Pathol. 2011;24(7):983–92. https://doi.org/10.1038/modpathol.2011.45.CrossRefPubMed

98.

Nairismagi ML, Tan J, Lim JQ, et al. JAK-STAT and G-protein-coupled receptor signaling pathways are frequently altered in epitheliotropic intestinal T-cell lymphoma. Leukemia. 2016;30(6):1311–9.CrossRefPubMedPubMedCentral

99.

Roberti A, Dobay MP, Bisig B, Vallois D, Boéchat C, Lanitis E, et al. Type II enteropathy-associated T-cell lymphoma features a unique genomic profile with highly recurrent SETD2 alterations. Nat Commun. 2016;7:12602. https://doi.org/10.1038/ncomms12602.CrossRefPubMedPubMedCentral

Titel: Updates of Peripheral T Cell Lymphomas Based on the 2017 WHO Classification
verfasst von: Parwiz J. Siaghani
Joo Y. Song
Publikationsdatum: 14.02.2018
Verlag: Springer US
Erschienen in: Current Hematologic Malignancy Reports / Ausgabe 1/2018
Print ISSN: 1558-8211
Elektronische ISSN: 1558-822X
DOI: https://doi.org/10.1007/s11899-018-0429-y

Neu im Fachgebiet Onkologie

10.04.2024 | PSA-Screening | Nachrichten

Springer Medizin

Updates of Peripheral T Cell Lymphomas Based on the 2017 WHO Classification

Abstract

Purpose of Review

Recent Findings

Summary

Neu im Fachgebiet Onkologie

Einladung zum PSA-Screening senkt die Krebssterblichkeit

Chemotherapie mit Hindernissen

Das Ende der vollständigen axillären Lymphknotendissektion

Senkt Schlafapnoe das Überleben bei Lungenkrebs?

Update Onkologie

Springer Medizin

Abstract

Purpose of Review

Recent Findings

Summary

Bitte loggen Sie sich ein, um Zugang zu diesem Inhalt zu erhalten

Weitere Artikel der Ausgabe 1/2018

The Future of Combination Therapies for Peripheral T Cell Lymphoma (PTCL)

NK/T Cell Lymphoma: Updates in Therapy

Twitter Use in the Hematopoietic Cell Transplantation Community

Immunologic Milieu of Mature T-Cell and NK-Cell Lymphomas—Implications for Therapy

Rethinking Antimicrobial Prophylaxis in the Transplant Patient in the World of Emerging Resistant Organisms—Where Are We Today?

Central Nervous System Involvement in Peripheral T Cell Lymphoma

Neu im Fachgebiet Onkologie

Einladung zum PSA-Screening senkt die Krebssterblichkeit

Chemotherapie mit Hindernissen

Das Ende der vollständigen axillären Lymphknotendissektion

Senkt Schlafapnoe das Überleben bei Lungenkrebs?

Update Onkologie